Kuala Lumpur’s Subang Jaya Medical Centre has begun administering lecanemab to patients with early symptomatic Alzheimer’s disease after Malaysian regulators granted full approval earlier this year, marking a rare, disease‑modifying therapy entering routine practice in the country. Early analyses presented internationally suggest the medicine may slow clinical progression for some groups by multiple years, reframing expectations for patients, families, and the health system.
A disease‑modifying therapy enters Malaysian practice
Alzheimer’s disease remains the leading cause of dementia, with profound consequences for independence, caregiving, and health‑system demand. Lecanemab, developed by Eisai, is an anti‑amyloid monoclonal antibody indicated for patients at the earliest symptomatic stages and marketed globally under the brand name Leqembi.
“Lecanemab is a very promising advance in the treatment of Alzheimer’s disease,” said Dr Chin Ai‑Vyrn, a consultant geriatrician at Subang Jaya Medical Centre.
“The evidence from clinical trials and real world studies show that lecanemab changes the trajectory and slows the progression of Alzheimer’s disease. By doing so, it helps patients with early symptomatic Alzheimer’s disease remain independent for longer.”
Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) approved the drug for early Alzheimer’s disease, with Subang Jaya Medical Centre becoming the first site to deliver infusions. The therapy previously received United States Food and Drug Administration approval in January 2023 for early symptomatic disease, following Phase 3 data showing a statistically significant slowing of decline in cognition and daily functioning over 18 months in appropriately selected patients.[2]
Clinicians and policymakers alike see the Malaysian launch as an inflection point: it is the country’s first routinely available biologic aimed at modifying the underlying trajectory of Alzheimer’s, rather than solely managing symptoms, and will test how quickly a middle‑income health system can adapt to complex neurodegenerative therapies.
How the medicine works on the amyloid pathway
Alzheimer’s pathology features abnormal accumulation of amyloid followed by tau, processes linked to neuronal dysfunction and cell loss. Lecanemab targets soluble and insoluble aggregated amyloid to facilitate immune‑mediated clearance in the brain, with trial imaging showing reductions in amyloid burden and downstream slowing of tau accumulation in treated patients compared with placebo.[3]
“Lecanemab is an antibody that targets amyloid. It’s given through the bloodstream and passes the blood brain barrier into the brain.”
“It then binds to the amyloid protein, and this stimulates our immune system to then remove this protein from the brain itself. So it gets rid of this protein, the amyloid protein from the brain,” Dr Chin said.
Clinically, expectations must be calibrated: symptomatic improvement is not the goal; slowing progression is, particularly when treatment is initiated before substantial neuronal loss has occurred.
“It doesn’t stop disease progression. But what it does is it slows the progression of the disease so that you don’t move from an earlier stage of disease to a more advanced stage so quickly,” said Dr Chin.
Global experts now describe lecanemab and similar agents as “secondary prevention” tools in carefully selected individuals, with ongoing trials exploring whether starting even earlier, in pre‑symptomatic high‑risk populations, might further delay onset of noticeable impairment.[1]
Lecanemab at a glance
| Domain | Details |
|---|---|
| Indication | Early symptomatic Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s or mild dementia stage), in patients with confirmed amyloid pathology and without major contraindications. |
| Mechanism | Humanised IgG1 monoclonal antibody targeting aggregated amyloid, designed to clear protofibrils and plaques implicated in synaptic dysfunction. |
| Administration | Intravenous infusion on a biweekly schedule under specialist supervision, with structured observation for infusion reactions and early adverse events. |
| Diagnostic requirement | Biological confirmation of amyloid pathology prior to treatment initiation, through cerebrospinal fluid or validated blood‑based biomarkers in settings where amyloid PET is unavailable. |
| Key safety focus | Amyloid‑related imaging abnormalities (ARIA) risk management and MRI monitoring, especially in patients carrying high‑risk APOE genotypes or on concomitant anticoagulants. |
| Eligibility window | Restricted to early stages; not indicated for moderate or severe Alzheimer’s disease, where clinical benefit has not been demonstrated and risk-benefit balance is less favourable. |
Who qualifies: confirming early disease and proving pathology
“The key criteria for the use of lecanemab in patients with dementia are, firstly, you need to have pathological proof that you have Alzheimer’s disease, and secondly, that you are at an early stage of the disease,” said Dr Chin.
- Clinical stage: mild cognitive impairment or mild dementia where independence is largely preserved but complex tasks may be affected, typically corroborated by standardised neuropsychological testing.
- Pathology confirmation: amyloid biomarker positivity is required prior to therapy, to avoid exposing patients with non‑Alzheimer’s dementias to unnecessary risk.
- Baseline imaging and labs: MRI to screen for microbleeds or significant vascular changes; genetic testing (APOE) to inform risk stratification and counselling; comprehensive cognitive assessment to establish a baseline for tracking progression.
Access to biomarkers is evolving within Malaysia. Amyloid PET-the historical gold standard-remains unavailable in the country, prompting wider use of lumbar puncture and newer blood assays that can be deployed more broadly in both public and private sectors.
“But at the end of last year, what became available was a blood test to test for a blood biomarker called p‑tau217, which can also offer biological proof that you have Alzheimer’s disease. It is nearly as accurate as an amyloid PET scan.”
For hospital administrators and payers, these eligibility criteria translate into the need for clear referral pathways: primary‑care and general neurology services must be able to identify suitable candidates early and channel them into centres with the diagnostic and monitoring infrastructure required for safe prescribing.
Measuring benefit: independence and “time gained”
Rather than reversing symptoms, the primary value of therapy lies in extending the period of relative independence before more intensive care is needed, a metric increasingly framed as “time gained” at a given level of functioning.
“We want to slow down the progression in terms of the time it takes for patients to change from a mild stage, where patients are independent, to a more severe stage, where patients are dependent and need help with their activities of daily living, and where there are issues in terms of whether or not the patients can be safely left on their own,” he explained.
- Clinical goal: delay transition from mild stages to more advanced dementia, keeping patients engaged in daily routines, employment, or caregiving roles for longer.
- Emerging data: analyses presented internationally suggest that for certain subgroups, disease progression could be delayed by up to 8.3 years with continued treatment, a finding that will require ongoing real‑world validation and careful communication to avoid over‑promising at individual level.
- Health‑system relevance: even modest delays in decline can meaningfully reduce caregiving intensity and defer high‑cost, high‑acuity services, including long‑term institutional care and emergency admissions related to advanced dementia complications.
For ministries of health and social‑care planners, the key question is not only whether lecanemab works in ideal trial conditions, but whether Malaysia can build the integrated care pathways to capture these potential “time gains” at scale without widening inequities between urban and rural populations.
Safety oversight and monitoring expectations
Anti‑amyloid treatments carry known risks that require structured monitoring and rapid response pathways in centres delivering care. International experience has underscored the importance of conservative dosing, strict adherence to MRI schedules, and informed consent that explicitly addresses rare but serious complications.
- ARIA surveillance: vigilance for ARIA‑E (edema) and ARIA‑H (microhemorrhage); greater risk has been observed in individuals with certain APOE genotypes, necessitating genotype‑informed counselling and, in some cases, altered dosing or treatment avoidance.
- MRI schedule: baseline MRI and periodic follow‑up scans in the early treatment phase, with additional imaging if neurological symptoms emerge, embedded into standard operating procedures rather than left to ad hoc clinical judgment.
- Infusion‑related reactions: observation during and after infusions; pre‑specified protocols for temporarily holding or adjusting therapy in the event of significant adverse events, with clear escalation routes to neurology and intensive care teams.
- Pharmacovigilance: timely adverse event reporting to the NPRA and participation in local registries to support safety signal detection, outcome tracking, and future health‑technology assessments.
Hospital leaders authorising lecanemab services are effectively committing to a medium‑term governance framework: multidisciplinary case conferences, centralised review of MRI findings, and routine audit of safety events will be essential to maintain public confidence.
System readiness: where Malaysian capacity will decide impact
Effective, equitable use of lecanemab hinges on diagnostic infrastructure, specialist expertise, and infusion capability. Subang Jaya Medical Centre’s early start signals feasibility, but scaling nationwide will require coordinated planning between tertiary centres, state health departments, and payers.
| Domain | Minimum capability required |
|---|---|
| Diagnostics | Access to validated biomarkers (CSF or blood p‑tau217), MRI capacity for screening and follow‑up, neuropsychology services for baseline and serial assessments. |
| Clinical governance | Multidisciplinary eligibility review; informed consent processes that reflect benefit-risk uncertainty at individual level; alignment with national dementia strategies where they exist. |
| Infusion services | Biweekly infusion slots, trained nursing staff, emergency response protocols for infusion reactions, and integration with pharmacy cold‑chain and biologics handling standards. |
| Genetic risk stratification | APOE testing with pre‑ and post‑test counselling to support shared decision‑making and documentation of patient preferences regarding known risks. |
| Data systems | Participation in treatment registries; integration of imaging, biomarker, and outcomes data to inform practice and policy, including cost‑effectiveness evaluations. |
| Financial access | Transparent pricing; coverage policies to reduce out‑of‑pocket burden; patient navigation for eligibility and follow‑up so that complex work‑ups and repeated MRIs do not become de facto barriers to care. |
For Malaysia’s public hospitals, the policy decisions taken in the next 12-24 months-on reimbursement, centre accreditation, and training-will determine whether lecanemab remains a niche private‑sector technology or becomes part of a broader, nationally coordinated dementia response.
Population‑level stakes as Malaysia ages
- Demographic trajectory: Malaysia’s rapidly ageing population will drive higher dementia prevalence; local clinicians project more than 600,000 people could be living with dementing syndromes by 2050, with disproportionate impact on women as both patients and unpaid carers.
- Potential system effects of lecanemab: delayed functional decline could reduce near‑term institutional care needs, but infusion and imaging demand will rise, requiring capital investments and workforce planning that extend beyond neurology departments.
- Policy levers: pathway standardisation, centre accreditation, safety registries, and equitable financing will determine whether benefits reach beyond urban tertiary hospitals and align with broader healthy‑ageing and non‑communicable disease strategies.
“It is something that changes the goalposts as to what we can do for early Alzheimer’s disease.”
As more secondary‑prevention trials report out and additional anti‑amyloid and anti‑tau agents approach regulatory decisions, Malaysia’s experience with lecanemab is likely to shape future negotiation power, pricing benchmarks, and expectations among patients’ groups across the region.
Beyond pharmaceuticals: risk reduction remains essential
Even as disease‑modifying options expand, non‑pharmacological strategies and management of co‑morbidities remain central to public‑health planning and individual outcomes, particularly for the vast majority of older adults who will not meet criteria for biologic therapy.
“We have good evidence that lifestyle factors are very important and what we do in our daily life such as exercise, a healthy diet, social interaction, good sleep, cognitive stimulating activities, all help to reduce the risk of developing dementia.
“It’s also important to optimally manage conditions such as diabetes, hypertension, high cholesterol to reduce your vascular risk. You also have to address conditions such as hearing or visual loss. All these things are part and parcel of reducing risk of progression, regardless of what medication that you use.”
For policymakers, that dual message-targeted access to high‑cost biologics on one hand, and population‑wide investment in brain‑healthy environments on the other-will be critical to ensuring that the arrival of lecanemab strengthens, rather than distorts, Malaysia’s broader dementia strategy.
